A detailed history of Veriti Management LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Veriti Management LLC holds 6,368 shares of HALO stock, worth $300,314. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,368
Previous 6,564 2.99%
Holding current value
$300,314
Previous $343,000 6.12%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$51.3 - $64.42 $10,054 - $12,626
-196 Reduced 2.99%
6,368 $364,000
Q2 2024

Aug 02, 2024

BUY
$37.81 - $52.4 $53,123 - $73,622
1,405 Added 27.23%
6,564 $343,000
Q1 2024

Apr 19, 2024

SELL
$33.68 - $41.95 $16,637 - $20,723
-494 Reduced 8.74%
5,159 $209,000
Q4 2023

Feb 05, 2024

BUY
$33.32 - $42.1 $188,357 - $237,991
5,653 New
5,653 $208,000
Q2 2023

Jul 13, 2023

BUY
$30.28 - $38.74 $115,972 - $148,374
3,830 Added 50.79%
11,371 $410,000
Q1 2023

Apr 26, 2023

BUY
$32.86 - $55.7 $4,238 - $7,185
129 Added 1.74%
7,541 $287,000
Q4 2022

Jan 20, 2023

BUY
$40.06 - $59.44 $7,290 - $10,818
182 Added 2.52%
7,412 $0
Q2 2022

Jul 18, 2022

SELL
$37.35 - $48.3 $7,357 - $9,515
-197 Reduced 2.65%
7,230 $318,000
Q1 2022

Apr 11, 2022

BUY
$31.97 - $41.06 $29,124 - $37,405
911 Added 13.98%
7,427 $296,000
Q4 2021

Jan 19, 2022

BUY
$31.82 - $40.75 $1,304 - $1,670
41 Added 0.63%
6,516 $262,000
Q3 2021

Oct 08, 2021

SELL
$38.47 - $46.42 $41,201 - $49,715
-1,071 Reduced 14.19%
6,475 $263,000
Q2 2021

Jul 13, 2021

BUY
$38.84 - $51.31 $97,721 - $129,095
2,516 Added 50.02%
7,546 $343,000
Q1 2021

Apr 14, 2021

BUY
$39.51 - $51.45 $12,169 - $15,846
308 Added 6.52%
5,030 $210,000
Q4 2020

Feb 11, 2021

BUY
$25.81 - $43.62 $121,874 - $205,973
4,722 New
4,722 $202,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Veriti Management LLC Portfolio

Follow Veriti Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Veriti Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Veriti Management LLC with notifications on news.